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Introduction: The aim of the present report was to draw the attention of oncologists to the importance of prompt
diagnosis of primary clear cell adenocarcinoma of the lung, which allows early initiation of treatment to maintain
quality of life.
Case presentation: A 63-year-old Chinese woman initially presented to our facility with multifocal bilateral choroid
metastatic lesions that were found to originate from a primary clear cell adenocarcinoma of the lung (T2bN2M1b,
stage IV). A thorough ophthalmologic evaluation, study of our patient’s history, imaging studies and comprehensive
immunohistochemical staining tests led to the diagnosis of this rare lung tumor.
Conclusions: Although this uncommon cancer is unfortunately already at a late stage when choroid metastases
develop, systemic chemotherapy alone is sufficient to preserve vision and gain control over the disease.Introduction
Choroid metastasis (CM) is the most common intra-
ocular neoplasm in adults, and the most common sites
for the primary tumors are the breast and lung [1-4].
The presence of such metastases suggest hematogenous
spread, an advanced stage of cancer therefore giving a
poor prognosis [5]. The prompt detection of CM is of
great significance as, with consideration of the perform-
ance status of the patient and location of the primary
tumor, it can lead to early implementation of appropriate
therapeutic management to improve disease control.
Multiple foci and bilateral involvement are important
clinical presentations of CM that can lead to the correct
diagnosis of the primary malignancy [1]. Clear cell adeno-
carcinoma of the lung with an abundant clear cell compo-
nent is extremely rare, and the associated biological
behavior and treatment outcomes for this illness are un-
known. Here, we present a case of primary clear cell
adenocarcinoma of the lung with multifocal bilateral CM
as the initial presentation in an otherwise healthy woman* Correspondence: yehtyng@gmail.com
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reproduction in any medium, provided the orwho had a significant and durable response to systemic
chemotherapy using cisplatin and pemetrexed.Case presentation
A 63-year-old Chinese woman presented to our facility
with a history of bilateral photopsia and blurred vision
for the last two months. She had no history of seizure,
vomiting, head injury, or exposure to medications that
could cause such effects. A thorough ophthalmological and
systemic examination was carried out. An ocular examin-
ation showed best corrected visual acuity of 20/100 in the
right eye and 2/80 in the left eye. A fundoscopic examin-
ation revealed the presence of multiple choroidal masses in
both eyes (Figure 1A,B). An ultrasonographic evaluation of
the eye demonstrated elevated choroidal masses in both
eyes with a maximal elevation of 3.2mm (Figure 1C,D). A
physical examination showed skin nodules over the chest
and abdominal areas. The pathology of the skin nodules re-
vealed metastatic clear cell adenocarcinoma of unknown
origin. Computerized tomography of the chest, abdomen
and pelvic area was performed. A mass in the left upper
lobe of the lung with several enlarged mediastinal lymph
nodes was detected. Moreover, skin nodules were found
on the chest and abdominal walls, and a left adrenal
nodule was also present (Figure 1G,H). A bone scanLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Choroid and skin metastases of primary clear cell adenocarcinoma of lung. (A-F) Ophthalmology images; (A,C,E) right eye,
(B,D,F) left eye. (A,B) Fundus appearance before treatment (arrows point to lesions); (C,D) ultrasound scan of the same eyes as in (A,B) before
treatment (arrows point to lesions); (E,F) lesion resolution by ultrasound scan of the same eyes as in (A,B) after treatment. (G) Appearance of skin
metastasis (arrow). (H) Chest computed tomography scan showing left upper lobe mass (1.3cm in diameter) (arrow).
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went a video-assisted thoracic surgical (VATS) biopsy to
obtain adequate material to establish a pathological
diagnosis. Histologically, the tumors from lung paren-
chyma, pleura and mediastinal lymph nodes were infil-
trated by core-like or abortive glandular structures that
consisted of pleomorphic clear tumor cells with foamy
cytoplasm and distinct nucleoli (Figure 2A,B). Immuno-
histochemical (IHC) staining test results showed that
the tumor cells were positive for pancytokeratin (AE1/
AE3) (Figure 2C), cytokeratin 7 (CK-7) (Figure 2D),
thyroid transcription factor 1 (TTF-1) (Figure 2E) and
carcinoembryonic antigen (CEA) (Figure 2F). The re-
sults for Ki-67 staining displayed a proliferative index of
approximately 45 to 50 percent (Figure 2G). Results of a
histochemical stain showed tumor cells positively stained
by periodic acid Schiff (PAS) and PAS with diastase indi-
cated the presence of glycogen (Figure 2H) In contrast,the tumor cells tested negative for CK-5/6, CK-20,
vimentin, thyroglobulin, CD10, CDX2, epithelial mem-
brane antigen (EMA), transcription factor E3 (TFE-3),
α-inhibin, Hep-par-1, glypican-3, p63 and HMB-45
(data not shown). The clinical and pathological features
of our patient’s case were compatible with a clear cell
adenocarcinoma of the lung (T2bN2M1b, stage IV, ac-
cording to the American Joint Committee on Cancer
(AJCC) cancer staging guide, seventh edition).
Systemic chemotherapy with pemetrexed (500mg/m2,
every three weeks) and cisplatin (75mg/m2, every three
weeks) was initiated. After cycle six of chemotherapy, a
fundoscopic examination showed near complete reso-
lution of the choroidal masses, coinciding with improve-
ment in her vision (Figure 1E,F). Although her cancer
status outside the orbit remained stable, she had a good
quality of life with no chemotherapy maintenance for
over 24 months at the time of this report.
Figure 2 Histopathological findings of primary clear cell adenocarcinoma of the lung. Hematoxylin and eosin staining showed that
the main tumor was infiltrated by pleomorphic clear tumor cells with foamy cytoplasm and distinct nucleoli ((A), 100×; (B) 400×). Positive
immunohistochemical staining results included pancytokeratin AE1/AE3 (C), cytokeratin 7 (D), thyroid transcription factor 1 (E), Ki-67 (G),
carcinoembryonic antigen (F) and periodic acid Schiff (H). Negative immunohistochemical stainings included HMB-45, Hep-par-1, transcription
factor E3, α-inhibin, S-100 and CDX2 (data not shown).
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Adenocarcinoma with cells that are filled with clear cyto-
plasm and that are the major component of a lung tumor
is defined as primary clear cell adenocarcinoma of the
lung according to World Health Organization classifica-
tion guidelines [6]. Because such pulmonary adenocarcin-
omas are very small in number, and the cases reported in
the literature have shown varied biological natures and
clinical presentations [7], the appropriate diagnostic pro-
cedures may help to establish an accurate diagnosis.
Firstly, it is so histologically heterogeneous for pulmonaryadenocarcinomas that we used video-assisted thoraco-
scopy to acquire enough tumor tissue, even though a fine-
needle aspiration biopsy may enable early diagnosis and
hence the initiation of immediate appropriate palliative
therapy. Secondly, comprehensive IHC staining studies
are required. The tumor tissue from our patient showed
monotonous clear cells arranged in a glandular pattern,
positive immunoreaction results for AE1/AE3, CK-7,
TTF-1, CEA, Ki-67, and positive PAS staining for the
existence of glycogen in clear cell cytoplasm. Thus, our
patient’s tumor met the criteria for primary clear cell
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was distinguished from tumors with clear cell cytoplasm
in any organs. Our patient’s tumor was different from
renal clear cell carcinoma because there was no tumor
found on imaging studies and the tumor cells were nega-
tive for CD10 staining. It was not a benign clear cell sugar
tumor because it was malignant and the tumor cells were
negative for HMB-45. Our patient’s case was not one of
clear cell squamous cell carcinoma in terms of histological
features and negative staining for p63. It was obviously
not a pulmonary blastoma or fetal adenocarcinoma be-
cause no fetal features were present. Our patient’s tumor
was not a metastatic thyroid papillary clear cell carcinoma
because there was no tumor found in the thyroid glands
and no expression of thyroglobulin. Our patient’s case was
not one of clear cell sarcoma, malignant melanoma, sex-
cord tumor and metastatic hepatocellular carcinoma, al-
veolar soft part tumor and metastatic carcinomas of the
gastrointestinal tract because there was negative staining
for HMB-45, S-100, α-inhibin, Hep-par-1, glypican-3,
CDX2, TFE-3 and vimentin. Taken as whole, our patient’s
clinical presentation, imaging study results and thorough
investigation of pathological features and IHC stainings
were sufficient to confirm the diagnosis of her tumor as a
primary clear cell adenocarcinoma of the lung with multi-
focal and bilateral CM, even without a choroid biopsy.
The incidence of CM for lung cancer is reported to be
no more than 7 percent [8]. In such a condition, the lung
cancer is already at a late stage and dissemination of the
disease has occurred; the median survival after diagnosing
symptomatic CM is 4.3 to 7.4 months [9]. Hence, the
goals of treatment are to improve quality of life and pre-
serve vision, which can be achieved by either systemic
chemotherapy or target therapy based upon the perfor-
mance status and the histologic subtype. It has been de-
monstrated that inhibition of the epidermal growth
receptor (EGFR) pathway with tyrosine kinase inhibitors
(TKIs) provides effective treatment and improved toler-
ability for non-small-cell lung cancers, especially for a
subset of female patients of East Asian origin who are
never smokers and have an adenocarcinoma histology,
and who have high prevalence of sensitive activating
EGFR mutations (deletion in exon 19 or point mutation of
L858 in exon 21) [10]. However, TKIs were not considered
since the tumor specimen from our patient failed to show
the aforementioned EGFR mutation.
It has been reported that systemic chemotherapy is effi-
cacious for choroid metastases from non-small-cell lung
cancer [11,12]. In our patient’s case, standard platinum
doublet chemotherapy was used as the initial and primary
treatment because our patient had other concurrent sites
of metastatic disease that required simultaneous attention.
Further, cisplatin plus pemetrexed has shown survival
benefits in pulmonary adenocarcinoma [13]. Although thetumor remained stable, our patient gained visual improve-
ment and acceptable disease control via this platinum
doublet chemotherapy. Taken together, these findings sug-
gest the choroid may be no longer considered as a ‘sanctu-
ary site’ to chemotherapy, and systemic chemotherapy
alone is a useful therapeutic option for CM of lung cancer.
The prognosis and treatment choices for primary clear
cell adenocarcinoma of the lung may resemble those for
non-small-cell lung cancer. Because the disease is rare
and glycogen-rich clear cells display an unusual hist-
ology, the prognosis and treatment outcome may be
more complicated. Even though a patient may initially
present with multiple metastases including the choroidal
type, as in our patient’s case, immediate initiation of
histologically-adapted chemotherapy may yield clinical
benefits and improvements in quality of life. To the best
of our knowledge this is the first report demonstrating
that the efficacy and safety of systemic doublet chemo-
therapy with cisplatin plus pemetrexed for choroidal
metastasis of primary clear cell adenocarcinoma of the lung.
Conclusions
In summary, we present a rare occurrence of clear cell
adenocarcinoma of the lung that needed to be confirmed
and differentiated from clear cell cancer from other or-
gans by systemic investigation and intensive IHC stain-
ing tests. CM may be the initial sign of this rare tumor
and the ophthalmologic diagnosis may lead to the dis-
covery of the systemic affliction, albeit unfortunately at a
late stage of the disease. If compatible with the patient’s
general status, appropriate chemotherapy may be an effi-
cacious mode of treatment in advanced stages of this
rare and metastatic lung cancer.
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